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Running title: Cisplatin’s effects on element metabolism 
Abstract 
 Nowadays several papers deal with the effectiveness and side effects of metal complexes, 
especially cisplatin, in cancer therapy. The excretion of essential metal elements from the body is a 
serious problem in the treatment, but there are no data concerning the distribution and metabolism of 
toxic and nonessential elements. Therefore our aim was to study the concentration of some of these 
elements after treatment with cisplatin. Male Wistar rats (n=20, 175-190 g) were randomly divided into 
2 groups (n=10/group). The control group received 1% (w/v) methyl cellulose at 10 mL/kg body 
weight, p.o. by gastric gavage twice daily for 14 days, while cisplatin was injected i.p. in a single dose 
of 6.5 mg/kg body weight. Inductively coupled plasma optical emission spectrometry (ICP-OES) was 
used for measuring Al, B, Ba, Cr, Li, Ni, Pb, Pt, Sb, Si, Sn, Sr and V content in plasma, liver and 
kidney. Liver total scavenger capacity, diene conjugate content and malondialdehyde concentration 
were also determined. Cisplatin elevated the free radical reactions in the liver, although redox balance 
did not change significantly. According to the study it seems that the metabolism of Al, Ba, Cr, Ni, Pb, 
Sr were changed by the effect of cisplatin, and the most notable alterations were found for Al and Pb. 
Therefore, besides the toxic effect of and free radical induction by Pt, the side effects of increased 
levels of other toxic and non-essential elements have to be taken into consideration. 
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Introduction 
 Cisplatin, oxaliplatin and carboplatin are known platinum derivatives, which are effective in the 
treatment of several tumors. Ciplatin (cis-diamminedichloroplatinum II, CDDP) is a widely used active 
anticancer agent in testicular, ovarian and bladder carcinomas,
 
head and neck squamous cell carcinoma, 
and non–small cell lung cancers [1]. Its use in clinical practice is restricted because of its strong side 
effects affecting mainly the liver and kidney [2]. Platinum complexes are well-known DNA alkylating 
agents, and their interaction with proteins may be a part of a series of molecular events [3]. They can 
modulate signal transduction pathways and induce apoptotic responses. Platinum
 
complexes induce the 
activation of members of the mitogen-activated protein
 
kinase (MAPK) family [4]. Inhibition of the 
constitutively activated signal transducers and activators of transcription (STAT) in malignant cells 
may be one of the key molecular mechanisms for the antitumor effects of platinum complexes. 
Platinum compounds disrupt STAT3 signaling and suppress its biological functions. New platinum 
complexes (CPA-1, CPA-7, Pt(IV)Cl4) block STAT3 activity in vitro at low micromolar 
concentrations. Contrary
 
to other reports on cisplatin, no significant
 
effects of these novel platinum(IV) 
complexes were observed
 
on ERK1/2, p38, JNK, Akt and Jaks, suggesting that direct modulation
 
of 
these signaling proteins may not contribute to the biological
 
effects of CPA-1, CPA-7, and Pt(IV)Cl4 
[4, 5, 6, 7]. 
 In a previous experiment treatment with cisplatin led to the depletion of essential elements such 
as Co, Cu, Fe, Mn, Mo, Se and Zn from the kidney [8] and increased excretion of Cu, Mg and Zn in the 
urine was observed by Pezonaga and her co-workers [9]. Nevertheless there are no data on the 
distribution and metabolism of toxic and nonessential elements that can be harmful to health in part by 
altering signaling pathways. Therefore our aim was to study how treatment with cisplatin changes the 
concentration of some of these elements in the plasma, liver and kidney of rats. 
 
Materials and methods 
Test material 
 Cisplatin (10 mg in 20 mL) was obtained from TEVA Pharmaceutical Industries, Petach Tikva, 
Israel.  
Animal experiment 
 Twenty male, 8-week-old Wistar rats weighing 175-190 g were randomly divided into 2 groups 
(n=10/group). They were kept individually under standard conventional conditions according to 
European Council Directive 123. The study conformed to the Declaration of Helsinki guidelines and 
was approved by the local animal ethical committee. 
 The control group received 1% (w/v) methyl cellulose at 10 mL/kg body weight p.o. by gastric 
gavage twice daily for 14 days. Cisplatin was injected intraperitoneally with a single dose of 6.5 mg/kg 
body weight [10]. Cisplatin was suspended in 10 mL/kg 1% methyl cellulose. For proving the effect of 
cisplatin to renal dysfunction, blood urea nitrogen (BUN) and creatinin levels were measured on day 
12. Rats were terminally anaesthetised with pentobarbitone on day 14.  
Rat samples 
 Blood was collected from the thoracic vena cava. Blood was anticoagulated with citrate and 
centrifuged twice at 2500 rpm for 10 min at +4 C to obtain plasma. 
 The kidneys were removed, washed and weighed. The liver was removed, weighed, washed and 
then homogenized in ice-cold isotonic KCl solution and the protein concentration was set at 10 g/L.  
Measurement of metal content 
 Plasma, liver and kidney samples were weighed (1 g plasma, 3.0-3.5 g liver homogenate and 1 
g kidney) into the digestion vessels. Plasma and liver samples were digested with 5 mL 65% nitric acid 
and 2 mL hydrogen peroxide, and kidney samples were digested with 10 mL 65% nitric acid and 2 mL 
hydrogen peroxide. The digestion was performed in a block digestion system because of the large 
amount of samples. After digestion and evaporation, the samples were poured into 10 mL volumetric 
flasks and were filled up to the mark with bidistilled water. Three plasma and liver samples and two 
kidney samples were prepared from each animal. 
 Inductively coupled plasma optical emission spectrometric (ICP-OES) method was applied for 
measuring Al, B, Ba, Cr, Li, Ni, Pb, Pt, Sb, Si, Sn, Sr and V content [11] using a Spectro Genesis ICP-
OES (Kleve, Germany) equipment. For the standardization of equipment and measurements, Spectro 
multi-element and Spectrum 3D standards were used. Standards were prepared in the same matrix as 
the samples. The samples were measured 3 times and blank subtraction was applied. The concentration 
of V was below detection limit in all samples; therefore this element was omitted from Tables 2, 3 and 
4. Furthermore, those metal elements were also omitted from the respective table that were below the 
detection limit in a certain sample (liver, kidney or plasma) in both groups.  
The detection limits for the samples (DL) were calculated from the instrumental detection limit 
(IDL) of elements, the weights of samples (W) and the final volumes (V) as follows: DL=IDL*V/W. 
The below detection limit concentrations for some elements are marked by the less-than sign (<) in 
Tables 2, 3 and 4. 
Metal element concentrations in bovine liver solution (High Purity Standards, CRM BL 
411213) were measured for the demonstration of reliability and precision of the measurement (Table 
1). The recovery (R) was calculated from the declared (DD) and measured values (MD) as follows: 
R=MD/DD*100. In the case of lead when the concentration was below the instrumental detection limit 
(IDL<0.02 μg/mL) and for those elements (B, Li, Sb, Sn, Sr, Pt), which had no certified data, the 
repeatability measurements were performed (five times) with standard solutions of 200 ng/mL and 500 
ng/mL concentration, and the recovery was calculated from these results (Table 1). 
Measurement of redox parameters of the liver 
 Total scavenger capacity (induced chemiluminescence assay) was determined with Berthold’s 
Lumat 9501 luminometer on the basis of a method developed by Blázovics and coworkers [12]. 
Chemiluminescent intensity of the liver homogenate was measured and expressed in relative light unit 
(RLU%) of the standard light (basic chemical reaction in H2O2/
.
OH–microperoxidase-luminol system). 
The protein content of the liver homogenate was set at 1% by the Lowry method [13].  
 The concentration of diene-conjugates was determined in the liver samples according to the 
description of Ahotupa and coworkers [14]. 
 In the liver homogenate malondialdehyde (MDA) levels were also measured 
spectrophotometrically by the method of Mansour and coworkers [15]. Trichloroacetic acid solution 
(20% w/v, 2.5 mL) and thiobarbituric acid (0.67% w/v, 1 mL) was added to the liver sample (0.5 mL) 
and shaken, and then heated for 30 min at 100 ºC. n-Butyl alcohol (4 mL) was added to the mixture and 
centrifuged at 3000 rpm for 10 min. The MDA content of n-butyl alcohol solution was calculated from 
the absorbance read at 535 nm and it was expressed as nmol/g. 
Statistical calculations 
 Means and standard deviations were calculated with MS-Excel, and ANOVA was applied for 
the determination of significant differences between groups by using GraphPad Prism 5.0 software. 
The level of significance was set at p<0.05. 
 
Results 
Metal element concentrations in the rat kidney  
 Treatment with cisplatin caused a more than 3-fold increase in Pb concentration in the kidney 
(p<0.05) at two weeks after cisplatin administration (Table 2). The concentration of Pt and Sb was 
below the detection limit in the vehicle-treated treated group. On the other hand, a huge increase in the 
concentrations of these two metal elements was observed in the group treated with cisplatin. The 
concentrations of other metal elements which could be detected in the kidney (Al, Ba, Cr, Ni, Pb, Si, 
Sn, Sr) did not change at two weeks after treatment with cisplatin. 
Metal element concentrations in the rat plasma  
Treatment with cisplatin increased the concentrations of several metal elements in the plasma (Al, 
B, Ba, Cr, Ni, Pb, Sb and Sr) in comparison to the group treated with vehicle (Table 3). Especially huge 
increases in the plasma concentrations of B, Pb and Sb were found in the group treated with cisplatin, 
as the concentrations of these metal elements were below the limit of detection in the vehicle-treated 
group, but were at least 13 to 300-fold higher at two weeks after treatment with cisplatin. 
The effects of cisplatin on the rat liver  
The concentration of Pt was below the limit of detection in the group treated with vehicle, while 
Pt concentration was detectable in the group treated with cisplatin. However, Pt concentration was 
much lower in the liver than in the kidney on day 14 after administration of the platinum complex 
(Table 4).  
The total scavenger capacity in the liver of the cisplatin-treated rats decreased as the amount of 
•OH/H2O2 radicals in the H2O2/•OH – microperoxidase-luminol-system was considerably higher in 
the liver of rats treated with cisplatin than in the liver of rats treated with vehicle (Fig. 1).  
The diene conjugate level in the liver decreased in the cisplatin-treated group (Fig. 2). Cisplatin 
increased the oxidation of lipids in the liver proved by the elevated malondialdehyde concentration in 
the liver homogenate (Fig. 3).  
 
Discussion 
In the liver Pt was detected in a small amount (Table 4) compared to that in the kidney. 
However, after treatment with a different platinum(IV) complex, LA-12, Sova and co-workers [16] 
published higher Pt accumulation in the liver. These contrary results suggest that the accumulation of 
Pt in the liver depends on the organic compounds used for complexation of Pt. In our study treatment 
with cisplatin at the dose applied did not affect other toxic and non essential element concentrations in 
the liver at two weeks after cisplatin administration. 
It has already been shown that cisplatin was significantly metabolized in the liver [17] and the 
metabolites were excreted by the kidney [2]. The liver damaging effect of toxic metal ions is hardly 
known. Toxic heavy metals are able to occupy the sites of essential elements and can cause toxicity 
through oxidative mechanisms [18]. We measured the total scavenger capacity of the liver because of 
the free radical generating ability of toxic elements, and the concentration of Pt increased in the liver of 
cisplatin-treated rats. The amount of •OH/H2O2 radicals in the H2O2/•OH – microperoxidase-luminol-
system were increased. This observation means a decrease in radical scavenging capacity of the liver 
similarly to that found in the plasma of cisplatin-treated rats in earlier experiments [8]. In line with the 
above finding the diene conjugate level decreased and the malondialdehyde concentration was elevated 
in the liver of the cisplatin-treated group. The mechanism of these changes was not addressed in this 
study but published results suggest that cisplatin can generate reactive oxygen and nitrogen species by 
increasing the activity of the cytochrome P450 system, NADPH oxidases, xanthine oxidase and 
adenosine deaminase. Cisplatin can also deplete glutathione and inhibit the activity of antioxidant 
enzymes [19, 20]. Nevertheless prooxidant and toxic effects of other metals should also be taken into 
account. These results collectively suggest that despite a small increase in the Pt concentration due to 
treatment with cisplatin the redox status and protection against oxidative stress was impaired in the 
liver. 
On the other hand, the kidney, the main organ of Pt-accumulation, contained a relevant amount 
of Pt (Table 2). Sabolic and co-authors [21] obtained similar results for Pt in the kidney after treatment 
of rats with cisplatin (5 mg/kg i.p.), however changes in other metal element concentrations were not 
studied by them. Cisplatin can damage organs, tissues and cells and the most serious toxic effect 
appears in the kidney, where Pt is accumulated [21, 22]. In our study, the concentration of Pb and Sb 
also increased in the kidney, while the concentration of other metal elements did not change. 
It is well-known that cisplatin administration resulted in serious histopathological changes and 
renal dysfunction that was related to the increase of renal vascular resistance and injury of proximal 
tubular cells [23, 24]. One of the main elimination pathways of toxic metals is excretion by the urine. 
Therefore, renal dysfunction can interfere with the ability to get rid of toxic metals in the body from the 
one hand, and can impair tubular reabsorption leading to depletion of some essential metal elements on 
the other hand. In fact, treatment with cisplatin decreased the levels of Cu, Mg and Zn in the plasma 
and led to the depletion of Cu, Mg and Zn essential elements by the urine in a human study [9]. 
Furthermore, in the rat kidney decreases in the concentration of some essential elements such as Co, 
Cu, Fe, Mn, Mo, Se and Zn was proved by us [8].  
As a consequence of decreased elimination of heavy metals the concentration of several toxic 
and non-essential elements increased in the plasma. In line with the high accumulation of Pb and Sb in 
the kidney their concentration was also markedly elevated in the plasma, but the levels of Al, B, Ba, Cr, 
Ni, and Sr were also increased. Metal elements bind mainly to plasma proteins. In the blood Al binds 
mainly to transferrin at the vacant sites of iron and to albumin in a smaller degree [25]. Chromium has 
similar properties to Al [26]. The main Ni-binding protein is also albumin, although α-macroglobulin 
and histidine can also react with this element in the plasma [27]. 
Cisplatin circulates in the blood bound to high molecular weight proteins and low molecular 
weight other compounds, as well as in the form of cisplatin aqua complexes [25]. Cisplatin is 
transformed to different metabolites in the organism. About fifty percent of cisplatin remained 
unchanged for more than one hour after treatment but cisplatin was fully transformed to some kind of 
metabolite within 24 hours [28]. The Pt-containing species disappear from the blood relatively rapidly. 
This may be a likely explanation for the observation that Pt was not detected in the plasma.  
According to the results of our study cisplatin accumulates in the liver to small extent. Despite a 
small increase in Pt concentration in the liver, the redox status and protection against oxidative stress 
was impaired in the liver. Cisplatin alters the metabolism of toxic and non-essential elements for a long 
period after treatment. As a result some metal elements accumulate in the kidney, but most toxic metals 
circulate in the blood at increased concentrations.  
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Table 1. Results of element concentration (mean±SD, ng/mL) in reference solution (Bovine liver 
solution, High Purity Standards, CRM BL 411213) standards and they recovery data 
Elements Declared 
concentration in 
reference solution 
Standard 
concentration 
Measured 
(n=5) 
Recovery 
(%) 
Al 200  199±2 99.5 
B  200 188±9 94.0 
Ba 10  10.5±0.5 100.5 
Cr 1  1.06±0.05 106.0 
Li  200 199±6 99.5 
Ni 2  1.94±0.05 97.0 
Pb 2 200 202±16 101.0 
Pt  500 502±2 100.4 
Sb  200 186±7 93.5 
Si 200  199±2 99.5 
Sn  200 203±17 101.5 
Sr  200 202±9 101.0 
V  200 199±100 99.5 
 
Table 2. Metal element concentrations (μg/g ± SD) in the rat kidney in the groups treated with vehicle 
and cisplatin (single dose of 6.5 mg/kg body weight) at 2 weeks after cisplatin administration. 
Elements Vehicle (n=10) Cisplatin (n=10) p value 
Al 5.66±1.32 6.58±2.60 >0.05 
Ba 0.092±0.042 0.083±0.058 >0.05 
Cr 0.135±0.027 0.149±0.021 >0.05 
Ni 0.154±0.061 0.135±0.050 >0.05 
Pb 1.29±0.73 4.36±3.50 <0.05 
Pt <0.035 3.30±0.32 <0.05 
Sb <0.02 0.739±0.137 <0.05 
Si 34.78±8.05 38.94±5.91 >0.05 
Sn 0.570±0.290 1.303±1.076 >0.05 
Sr 0.115±0.116 0.064±0.017 >0.05 
Table 3. Metal element concentrations (μg/g ± SD) in the rat plasma in the groups treated with vehicle 
and cisplatin (single dose of 6.5 mg/kg body weight) at 2 weeks after cisplatin administration. 
Elements Vehicle (n=10) Cisplatin (n=10) p value 
Al 1.01±0.29 3.11±2.79 <0.05 
B <0.05 15.05±13.96 <0.05 
Ba 0.089±0.042 0.183±0.128 <0.05 
Cr 0.029±0.013 0.068±0.056 <0.05 
Ni 0.057±0.027 0.124±0.074 <0.05 
Pb <0.2 2.58±1.58 <0.05 
Sb <0.02 1.82 <0.05 
Si 9.31±2.66 17.45±12.31 >0.05 
Sn 0.313±0.098 0.403±0.198 >0.05 
Sr 0.066±0.027 0.107±0.074 <0.05 
Table 4. Metal element concentrations (μg/g ± SD) in the rat liver of vehicle and cisplatin-treated rats 
(single dose of 6.5 mg/kg body weight) at two weeks after cisplatin administration. 
Elements Vehicle(n=10) Cisplatin(n=10) p value 
Al 0.501±0.169 0.572±0.369 >0.05 
B 0.960±0.730 2.08±2.42 >0.05 
Ba 0.058±0.107 0.223±0.593 >0.05 
Cr 0.013±0.003 0.014±0.006 >0.05 
Ni 0.037±0.042 0.045±0.060 >0.05 
Pb 0.152±0.079 0.118±0.130 >0.05 
Pt <0.010 0.021±0.002 <0.05 
Sb 0.147±0.060 0.120±0.050 >0.05 
Si 6.04±3.30 4.74±2.29 >0.05 
Sn 0.061±0.046 0.030±0.012 >0.05 
Sr 0.041±0.019 0.048±0.020 >0.05 
 
  
Figure .1. Total scavenger capacity expressed as Chemiluminescence chemiluminescence intensity 
(RLU % ± SD) in the liver of control- and cisplatin cisplatin-treated rats (single dose of 6.5 mg/kg 
body weight) measured the in H2O2/

OH -microperoxidase-luminol-system. 
  
 
Fig. 2. Diene conjugate content (absorbance ±SD, measured at 232 nm) in the liver of control and 
cisplatin cisplatin-treated rats (single dose of 6.5 mg/kg body weight) 
  
Fig.ure 3. Malondyaldehyde levels (nmol/g ±SD, measured at 535 nm) in the liver of control vehicle- 
and cisplatin cisplatin-treated rats (single dose of 6.5 mg/kg body weight) 
